Metoclopramide Ennogen Ip

Metoclopramide, the active ingredient in Metoclopramide Ennogen Ip, is a dopamine antagonist presented as an intravenous solution for IV use. It is employed to treat nausea, vomiting, gastroparesis, and migraine‑associated nausea in adult patients.

GNH USA supplies Metoclopramide Ennogen Ip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for import.

Metoclopramide acts on dopaminergic and serotonergic pathways to control emesis and improve gastric motility.

- Nausea and vomiting: reduces frequency and severity of acute and chemotherapy‑induced episodes. - Gastroparesis: enhances gastric emptying and alleviates related symptoms. - Migraine‑associated nausea: mitigates nausea accompanying migraine attacks.

Metoclopramide may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Drowsiness: mild sedation or fatigue. - Restlessness: feeling of inner tension or agitation. - Diarrhea: loose stools. - Headache: mild to moderate pain. - Extrapyramidal symptoms: transient muscle stiffness or tremor.

Serious or Rare Side Effects: - Tardive dyskinesia: irreversible involuntary movements with prolonged use. - Neuroleptic malignant syndrome: high fever, rigidity, autonomic instability. - Seizures: rare convulsive episodes. - Severe allergic reaction: rash, swelling, anaphylaxis.

When prescribing Metoclopramide, clinicians should consider several safety measures. - Renal impairment: adjust dose or monitor closely in patients with reduced kidney function. - History of movement disorders: avoid or use with caution in patients with Parkinson’s disease or dystonia. - Elderly patients: increased risk of extrapyramidal effects; monitor closely. - Concomitant CNS depressants: may enhance sedation; observe for additive effects. - Store below 25°C: keep in the original container, protect from light and moisture.

Metoclopramide can alter the activity of other medicines, requiring attention to potential interactions.

Major Interactions (Avoid): - Anticholinergic agents: may reduce pro‑kinetic effect; avoid concurrent use. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase metoclopramide plasma levels; avoid. - Other dopamine antagonists (e.g., haloperidol): additive risk of extrapyramidal symptoms; avoid.

Moderate Interactions (Monitor Closely): - Opioids: may enhance nausea; monitor response. - MAO inhibitors: risk of hypertensive crisis; use with caution. - Antihistamines: may increase sedation; observe patient.